Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJing LiuRXRuixian Xing

Discussion

Loading...

Member takes

Overview

Randomised trial finds improved efficacy and safety in primary CNS lymphoma patients, suggesting potential for broader use of chidamide.

Key Points

  • To evaluate the efficacy and safety of the MIEDD regimen with or without chidamide in newly diagnosed primary CNS T-cell lymphoma patients.
  • Conducted in HIV-negative patients with newly diagnosed primary CNS T-cell lymphoma.
  • Patients received 3-6 cycles of the MIEDD regimen over 21 days, plus oral chidamide.
  • Evaluated patients' response post-induction chemotherapy.
  • 72.7% achieved complete remission after induction therapy.
  • 68.2% estimated progression-free survival rate at 2 years.
  • No patients died of toxicity, indicating a good safety profile.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d2e2https://doi.org/10.1182/blood-2025-5418
View Full Paper
Ask AI
Bookmark
Share